Company: DVAX
Filing Date: 2025-05-23
Form Type: DEFA14A
Source: 0001193125-25-125825
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-23
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material Pursuant to §240.14a-12 |

Dynavax Technologies Corporation (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule 
 14a-6(i)(1) and 0-11.                                                         |

This Schedule 14A filing consists of the following press release distributed by Dynavax Technologies Corporation (the “Company”) to its stockholders in connection with the Company’s 2025 Annual Meeting of Stockholders. The press release was first used or made available on May 23, 2025. Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Four of Dynavax’s Highly Qualified Director Nominees ISS Recognizes There is No Case for Change Dynavax’s Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track’s Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote “FOR” ALL Four of Dynavax’s Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 23, 2025 — Dynavax Technologies Corporation (Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services (“ISS”), has recommended that Dynavax stockholders vote “FOR” all four of the Company’s director nominees standing for election – Brent MacGregor, Scott Myers, Lauren Silvernail